Science

Pipeline

Four R&D Programs based on BAPAI Platform:

  1.  Clinical Development of First-in-Class QGC001, the first drug candidate in the BAPAI class, for the treatment of high blood pressure
  2. Development of therapeutic combinations involving a BAPAI with another antihypertensive drug
  3. Optimization of BAPAI products and development of a “Best-in-Class” product
  4. Development of QGC101 product for the treatment of heart failure
stade d’avancement des différents projets

stade d’avancement des différents projets

QGC001

First-in-class : Treatment of hypertension as monotherapy

QGC011

Combination : Treatment of hypertension in combination

QGC006

Best-in-class : Optimized treatment of hypertension as monotherapy

QGC101

First-in-class : Prevention and treatment of congestive heart failure